Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a late-stage clinical radiopharmaceutical company developing targeted cancer drugs based on its proprietary Phospholipid Drug Conjugate (PDC) platform. The CLRB news feed on Stock Titan aggregates company announcements, scientific presentations and regulatory updates that reflect the progress of this oncology pipeline.
Investors and researchers following Cellectar’s news can track developments around its lead asset, iopofosine I 131, including data from the CLOVER WaM Phase 2b study in Waldenstrom’s macroglobulinemia, the CLOVER‑2 pediatric high‑grade glioma program, and investigator‑initiated work in head and neck cancer. News items also cover FDA designations such as Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease and Fast Track, as well as EMA PRIME and orphan designations and feedback from the EMA’s Scientific Advice Working Party on a potential Conditional Marketing Authorization filing in Europe.
The CLRB news stream highlights updates on Auger‑ and alpha‑emitting candidates CLR 121125 (CLR 125) and CLR 121225 (CLR 225), including preclinical data in triple‑negative breast cancer and pancreatic ductal adenocarcinoma, clinical trial planning, and supply agreements for key radioisotopes like actinium‑225 and astatine‑211. Financial results, capital raises, warrant transactions, and reverse stock split actions reported in SEC‑linked press releases provide additional context on how the company funds its development plans.
By monitoring this page, users can review historical and ongoing disclosures about Cellectar’s clinical results, regulatory interactions, partnerships and financing activities, all drawn from company-issued news and related filings.
Cellectar Biosciences (CLRB) announced positive results from a Phase 1 study of iopofosine I-131 for treating pediatric relapsed cancers, specifically high-grade gliomas and soft tissue sarcomas. The study showed promising tumor responses, with patients experiencing over 5 months of progression-free survival, almost double the historical norm of 2-3 months. The Data Monitoring Committee has approved dose escalations, suggesting the treatment is safe and tolerable. Cellectar plans to engage with the FDA on potential next steps for regulatory approval.
Cellectar Biosciences (NASDAQ: CLRB) reported Q3 financial results for the period ending September 30, 2021. The company completed Part A of a safety study for iopofosine in combination with external beam radiation for head and neck cancer. Preliminary data indicates safety and tolerability. They secured a $2 million NIH Phase II SBIR grant to support iopofosine’s pivotal study in Waldenstrom’s macroglobulinemia. Cash reserves stood at $40.3 million, but the company posted a net loss of $5.8 million for Q3, widening from a $3.9 million loss in 2020.
Cellectar Biosciences (NASDAQ: CLRB) announced Dr. Laurence Reilly as interim chief medical officer, succeeding Dr. John Friend, who departs for personal reasons. Dr. Reilly brings extensive experience in hematological oncology and is expected to lead Cellectar's clinical development programs, including the pivotal trial for iopofosine I-131 in treating Waldenstrom’s macroglobulinemia. The company remains financially stable and aims to advance its cancer treatment pipeline through ongoing trials and collaborations.
Cellectar Biosciences (NASDAQ: CLRB) has announced a collaboration with BBK Worldwide to enhance patient support services for participants in its clinical studies. This initiative aims to provide comprehensive concierge services, including transportation and assistance with reimbursement for cancer patients. The focal point of this collaboration is the ongoing pivotal study of iopofosine I-131 for Waldenstrom's macroglobulinemia. Cellectar is also engaged in additional clinical studies involving iopofosine for other hematologic malignancies.
Cellectar Biosciences (NASDAQ: CLRB) announced the initiation of an expansion cohort for the iopofosine I-131 study in patients with relapsed or refractory head and neck cancer. Following the completion of a safety phase, the University of Wisconsin will assess the potential of iopofosine combined with external beam radiation therapy (EBRT) to reduce radiation doses while maintaining tumor response. The study aims to enroll up to 24 patients and is part of a broader evaluation of iopofosine in various cancers. The company remains optimistic about the treatment's efficacy and safety.
On September 15, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced that CEO James Caruso will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, 2021, at 12:25 PM ET. The presentation will provide a company overview, highlighting its focus on developing targeted cancer therapies using its proprietary Phospholipid Drug Conjugate™ platform. Cellectar is currently conducting a pivotal Phase 2 study for its lead candidate, iopofosine, aimed at providing targeted delivery of iodine-131 for cancer treatment.
Cellectar Biosciences (NASDAQ: CLRB) announced a significant achievement on August 18, 2021, securing a $2 million Phase II NIH Small Business Innovation Research grant from the National Cancer Institute. This funding will bolster the ongoing pivotal study of iopofosine I-131 in treating Waldenstrom’s macroglobulinemia, which began in January 2021 and aims for full enrollment within 18 months. With over $46.8 million in cash equivalents reported as of June 30, 2021, the company is projected to sustain operations into Q3 2023, covering top-line data and NDA submission.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) has signed a commercial manufacturing and supply agreement with Evergreen Theragnostics to boost the production capabilities of iopofosine I-131. This partnership will enhance the supply for clinical studies, particularly for Waldenstrom’s macroglobulinemia, and future therapeutic programs. The USAN has designated 'iopofosine I-131' as the generic name for CLR-131. The collaborative effort aims to meet market demand in the U.S. and beyond, ensuring efficient distribution and production of this promising radiotherapeutic.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported its Q2 financial results for 2021, highlighting a net loss of $6.0 million, or $0.11 per share, compared to a $3.6 million loss in 2020. Cash and equivalents stood at $46.8 million. R&D expenses increased to $4.6 million due to costs related to a pivotal study for Waldenstrom’s macroglobulinemia. Positive data was presented on CLR 131, showing a 100% overall response rate in six patients. The company has announced two collaborations to expand its PDC therapeutics pipeline.
Cellectar Biosciences (NASDAQ: CLRB) has expanded its collaboration with IntoCell Inc. to further develop phospholipid drug conjugates (PDCs). This collaboration utilizes IntoCell's innovative OHPAS linker chemistry alongside Cellectar's phospholipid ethers to create new PDCs. The partnership has demonstrated sufficient preclinical success to proceed with IND-enabling studies. Cellectar retains rights to globally develop any resulting OHPAS-containing PDCs, enhancing its pipeline of targeted cancer therapies.